Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) vs Clascoterone: Bimatoprost (lashes) has the stronger overall evidence (8 vs 7/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Apply a thin layer of clascoterone 1% cream to the affected area twice daily, morning and evening, on clean dry skin
Morning and evening
Clascoterone 1% cream
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
immediate
12 weeks
12 weeks
1-4 weeks
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials
JAMA Dermatol (2020) · Rct · n=1440
The pivotal registration trials: two identical phase 3 studies, 1440 patients randomised, conducted November 2015 to April 2018.
Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
J Drugs Dermatol (2023) · Rct · n=1421
709 patients received clascoterone and 712 received vehicle in the pooled ≥12-year population.
Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials
Dermatol Ther (2021) · Meta analysis · n=2457
Five trials, 2457 patients (1357 clascoterone, 1100 placebo), overall low risk of bias.
Bimatoprost (lashes) has a higher evidence score (8/10 vs 7/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Clascoterone have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.